To find a reference on this page either scroll or hold down the "Ctrl" key and press "f".
|
paclitaxel
|
| breast cancer (PBAC question) 30(1) 24-5 |
| ovarian cancer - Taxol (New drug) 17(4) 87-90 |
|
Paediatric pharmacopoeia
|
| book review 26(2) 43 |
|
paediatrics - see children
|
|
Paget's disease of bone
|
| alendronate - Fosamax (New drug) 19(4) 108-11 |
| risedronate - Actonel (New drug) 24(1) 20-3 |
| tiludronate - Skelid (New drug) 21(3) 80-3 |
|
pain
|
| anticonvulsants in neuropathic pain 22(6) 140-1 |
| letter 23(4) 72 |
| emergency management of dental pain 24(6) 144-8 |
| management of dental and oral pain 30(3) 77-9 |
| managing painful paediatric procedures 29(4) 94-6; 29(4) 108 |
| letters 29(6) 149-50 |
| methadone in cancer 23(5) 93-6 |
| neuropathic - drug treatment 29(3) 72-5 |
| dental notes 29(3) 82 |
| non-organic in children 22(5) 122-5 |
| perioperative analgesia 27(6) 152-4 |
| letter 28(2) 29-33 |
| pethidine - in pain management 25(1) 12-3 |
| letter 25(4) 79-80 |
| Pharmaceutical Benefits Scheme restrictions on analgesics for the aged (PBAC question) 27(6) 155 |
| update 27(6) 155 |
| pregabalin - neuropathic pain - Lyrica (New drug) 28(3) 75-9 |
|
pain management
|
| opioids 19(3) 66-8 |
| paracetamol in children 18(2) 33-5 |
| postoperative 18(4) 88-91 |
|
palifermin
|
| Kepivance - oral mucositis prevention in chemotherapy (New drug) 28(6) 156-8 |
|
palivizumab
|
| RSV infection - Synagis (New drug) 22(5) 125-7 |
|
Palladone XL
|
| see hydromorphone 28(3) 75-9 |
|
palliative care
|
| morphine and methadone in cancer (letter) 23(5) 93-6 |
| non-malignant disease (editorial) 26(5) 98-9 |
| opioids 19(3) 66-8 |
| letter - dosage forms 20(1) 3-4 |
| pancreatic carcinoma 28(2) 42-4 |
| Therapeutic Guidelines - book review 29(3) 79; 25(1) 18 |
|
Paludrine
|
| see proguanil 19(1) 24-7 |
|
pamidronate
|
| see disodium pamidronate 23(6) 133-6; 22(2) 28-31 |
|
pancreatic carcinoma
|
| chemotherapy 28(2) 42-4 |
|
pandemics
|
| see disease outbreaks 30(2) 30-1; 25(3) 51-3 |
|
panic disorder
|
| management 23(6) 124-6 |
| letter 24(2) 27-8 |
| patient support organisation 23(6) 128 |
| panic disorder 22(5) 108-11 |
| letter 22(6) 131-2 |
|
pantoprazole
|
| proton pump inhibitor - Somac (New drug) 19(1) 24-7 |
| Somac (New formulation, new strength) 23(4) 84-7 |
|
papillomavirus vaccine
|
| Cervarix (New drug) 30(5) 133-5 |
| Gardasil (New drug) 29(5) 138-43 |
|
paracetamol
|
| in childhood fever 23(3) 60-1 |
| letter 23(6) 115-7 |
| gastrointestinal bleeding and hypertension (letter) 30(3) 59-63 |
| hepatotoxicity and alcohol 27(1) 14-5 |
| and ibuprofen in childhood fever (letter) 27(3) 55-7 |
| letter 28(2) 29-33 |
| NSAID interactions 20(3) 74 |
| over-the-counter medications and children 24(6) 149-51 |
| letter 25(2) 27-8 |
| toxicity 23(3) 60-1 |
| use in children 18(2) 33-5 |
|
paranasal sinuses
|
| sinusitis management 23(2) 39-42 |
|
parasomnia
|
| diagnostic tests 21(2) 40-3 |
| letter 22(1) 3-5 |
|
parathyroid hormone
|
| osteoporosis - teriparatide - Forteo (New drug) 27(1) 21-3 |
|
parecoxib
|
| postoperative analgesia - Dynastat (New drug) 25(4) 94-9 |
|
Pariet
|
| see rabeprazole 24(2) 43-7 |
|
Parkinson's disease
|
| dopamine pharmacology 17(1) 21-3 |
| drug treatment 24(4) 92-5 |
| entacapone - Comtan (New drug) 22(6) 147-51 |
| patient support organisations 24(4) 96-7 |
| pergolide - Permax (New drug) 17(4) 87-90 |
| personal experience 24(4) 95 |
| tolcapone - Tasmar (New drug) 21(2) 49-55 |
|
paroxetine
|
| antidepressant - Aropax (New drug) 17(2) 30-2 |
| costs and benefits of antidepressants (editorial) 18(4) 82-4 |
| product information (letter) 22(1) 3-5; 21(3) 60-3 |
| review of new antidepressants 18(4) 92-6 |
| selective serotonin reuptake inhibitors and suicide risk in children (editorial) 28(5) 111-3 |
| letter 29(2) 32-5 |
|
Patanol
|
| see olopatadine 25(6) 147-51 |
|
patents
|
| evergreening drug patents (editorial) 29(6) 148-9 |
|
pathology, diagnostic - see abnormal laboratory results
|
|
patient compliance
|
| Aboriginal children (letter) 26(2) 27-9 |
| Aboriginal patients 28(5) 123-5 |
| combination drugs 24(5) 127-9 |
| letter 24(6) 135-6 |
| consumers' vs doctors' perceptions of risk 26(2) 44-5; 26(1) 20-1 |
| doctor-patient relations 21(4) 92-4 |
| doses missed by patients 25(1) 16-8 |
| progestogen-only contraceptives (letter) 25(3) 51-3 |
| literature review and terminology 23(5) 103-4; 23(5) 105 |
| literature review and terminology - letter 24(3) 51-5 |
| medication reviews (letter) 17(4) 79-81 |
| methotrexate - adverse effects 23(2) 44-5 |
| letter 23(5) 93-6 |
| splitting tablets 25(6) 133-5 |
| letters 26(2) 27-9 |
|
patient experiences - see also patient's perspective
|
| cancer chemotherapy in the aged 23(4) 82-3 |
| DIPEx Website review 25(4) 93-4 |
| multiple sclerosis 25(2) 35-6 |
| panic disorder 23(6) 127-8 |
| Parkinson's disease 24(4) 95 |
| post-traumatic stress disorder 22(2) 34-6 |
|
patient histories
|
| recognising drug adverse effects 25(3) 73-4 |
| letter 25(5) 104-7 |
|
patient information - see also drug information
|
| cancer patients 19(2) 55 |
| consumer information about drugs 18(1) 10-1 |
| consumers' vs doctors' perceptions of risk 26(2) 44-5; 26(1) 20-1 |
| legal issues - informed consent 25(5) 114-5 |
| letter 18(2) 27-9 |
| methotrexate - adverse effects 23(2) 44-5 |
| letter 23(5) 93-6 |
| paracetamol 23(3) 61 |
| splitting tablets 25(6) 133-5 |
| letters 26(2) 27-9 |
|
patient support organisations
|
| Alzheimer's associations 19(1) 17 |
| Alzheimer's Australia 28(3) 72 |
| Arthritis Foundation of Australia 26(2) 45-6 |
| Asthma Australia 26(1) 21 |
| Australian Hepatitis Council 29(2) 39 |
| Australian Kidney Foundation 23(1) 20 |
| Australian Lung Foundation 30(3) 79 |
| Australian Myasthenic Association in NSW 30(6) 160 |
| Coeliac Society of Australia 24(2) 40-1 |
| Continence Foundation of Australia 29(1) 24 |
| Deafness Forum and Australian Hearing 26(4) 87 |
| Diabetes Australia 27(4) 96-7; 25(1) 10-1; 22(3) 69-70 |
| eating disorders 21(4) 105 |
| epilepsy 21(2) 39 |
| Glaucoma Australia 25(6) 146 |
| HIV/AIDS 26(3) 61 |
| lupus support groups 17(3) 61 |
| Meniere's Support Group 28(4) 107 |
| multiple sclerosis - MS Australia 25(2) 36-7 |
| panic and anxiety disorders 23(6) 128 |
| Parkinson's disease 24(4) 96-7 |
| post polio support groups 17(4) 103 |
| Quitline (smoking cessation) 28(3) 73-5 |
| Retina Australia 25(5) 115 |
| role in patient care 27(1) 19-21 |
| schizophrenia 22(4) 84 |
| Trigeminal Neuralgia Association of Australia 29(3) 75 |
| Vietnam veterans 22(2) 34-6 |
|
patient's perspective
|
| myasthenia gravis 30(6) 161 |
|
Paullinia cupana
|
| see guarana 21(1) 5-8 |
|
Paxam
|
| see clonazepam 20(1) 22-3 |
|
PBAC - see Pharmaceutical Benefits Advisory Committee
|
|
PBAC answers to questions
|
| influenza vaccination 30(3) 83 |
| specific drugs |
| adrenaline 28(4) 90 |
| auto-injectors - repeat prescriptions 28(4) 90 |
| shelf-life 29(2) 52-3 |
| analgesics and the aged 27(6) 155 |
| update 28(1) 11-3 |
| aprepitant as antiemetic in cancer chemotherapy 28(5) 119 |
| bisphosphonates, alendronate and osteoporosis 24(2) 41 |
| bupropion - heavy demand from smokers 24(3) 64 |
| celecoxib prescriptions and adverse effects 24(1) 7-8 |
| correction |
| folinic acid and colorectal cancer 26(4) 77 |
| glucosamine and osteoarthritis 28(2) 48 |
| laxatives in aged care 26(2) 32 |
| methylphenidate and attention deficit hyperactivity disorder 24(5) 119 |
| taxanes and breast cancer 30(1) 24-5 |
| tramadol adverse effects 27(2) 26-7 |
|
PBS - see Pharmaceutical Benefits Scheme
|
|
pediculosis capitis
|
| management 23(3) 62-3 |
| letters 24(1) 3; 23(5) 93-6 |
|
Pegasys
|
| see peginterferon alfa-2a/ribavirin 26(6) 146-51 |
|
Pegatron Combination Therapy
|
| see peginterferon alfa-2b/ribavirin 26(1) 22-3 |
|
pegfilgrastim
|
| neutropenia - Neulasta (New drug) 25(6) 147-51 |
|
peginterferon alfa-2a/ribavirin combination
|
| chronic hepatitis C - Pegasys (New drug) 26(6) 146-51 |
| hepatitis C 29(2) 36-9 |
|
peginterferon alfa-2b
|
| chronic hepatitis C - Peg-Intron (New drug) 25(5) 120-3 |
|
peginterferon alfa-2b/ribavirin combination
|
| hepatitis C 29(2) 36-9 |
| Pegatron Combination Therapy (New combination) 26(1) 22-3 |
|
Peg-Intron
|
| see peginterferon alfa-2b 25(5) 120-3 |
|
pemetrexed disodium
|
| Alimta - lung cancer, mesothelioma (New drug) 28(1) 19-23 |
|
penciclovir
|
| herpes labialis - Vectavir (New drug) 20(3) 77-9 |
|
Pendine
|
| see gabapentin 25(6) 147-51 |
|
penicillin
|
| allergy |
| cephalosporin cross-reactivity 30(1) 25-6 |
| testing 17(3) 62-5 |
|
Pentasa
|
| see mesalazine 27(4) 101-5 |
|
pentastarch
|
| Voluven - hypovolaemia (New drug) 30(4) 107-11 |
|
pentosan polysulphate sodium
|
| cystitis - Elmiron (New drug) 17(3) 73 |
|
peptic ulcer
|
| esomeprazole - Nexium (New drug) 25(4) 94-9 |
| Helicobacter pylori laboratory results 20(4) 96-8 |
| letter 21(2) 31-4 |
| lansoprazole - proton pump inhibitor - Zoton (New drug) 17(3) 73 |
| management 18(4) 97-9 |
| letter - barium meals vs endoscopy 19(3) 59-62 |
| management of gastrointestinal haemorrhage 28(3) 62-6 |
| letter 28(6) 136-9 |
| pantoprazole - proton pump inhibitor - Somac (New drug) 19(1) 24-7 |
| pharmacology of acid secretion inhibitors 23(3) 57-9 |
| proton pump inhibitors - long-term management 31(1) 5-7 |
| rabeprazole - Pariet (New drug) 24(2) 43-7 |
|
peptides
|
| cyclic citrullinated antibodies in rheumatoid arthritis 29(6) 162-4 |
|
perflutren
|
| Definity - ultrasound contrast medium (New drug) 30(4) 107-11 |
|
pergolide
|
| Parkinson's disease - Permax (New drug) 17(4) 87-90 |
|
perhexiline maleate
|
| angina pectoris - Pexid (New drug) 19(2) 38-40 |
|
perindopril
|
| patent evergreening (editorial) 29(6) 148-9 |
|
perindopril erbumine
|
| Coversyl (New strength) 27(2) 50-1 |
|
perindopril/indapamide
|
| Coversyl Plus (New combination) 23(5) 110-1 |
|
periodontitis
|
| adverse drug effects 29(6) 154-5 |
| and diabetes 27(2) 36-8 |
| drug-induced 26(1) 11-3 |
| management of dental and oral pain 30(3) 77-9 |
|
Permax
|
| see pergolide 17(4) 87-90 |
|
permethrin
|
| pediculosis capitis 23(3) 62-3 |
| letters 24(1) 3; 23(5) 93-6 |
| scabies management 23(2) 33-5 |
|
personal experiences of illness - see patient's perspective
|
|
pertussis - see also pertussis, diphtheria and tetanus vaccine
|
| childhood immunisation 17(4) 91-4 |
| letter - contraindications 18(3) 56-7 |
| triple antigen - Infanrix (New drug) 20(2) 45-51 |
| triple antigen - Tripacel (New drug) 21(4) 108-11 |
|
pertussis, diphtheria and tetanus vaccine
|
| diphtheria, tetanus, pertussis, hepatitis B, polio and Haemophilus influenzae type b - Infanrix penta, Infanrix hexa and Infanrix IPV (New combinations) 27(6) 159-65 |
| see triple antigen 24(4) 100-2 |
|
pethidine
|
| alternatives in migraine 20(3) 71 |
| letter 21(2) 31-4 |
| in labour pain 27(2) 34-5 |
| in pain management 25(1) 12-3 |
| letter 25(4) 79-80 |
|
Pexid
|
| see perhexiline maleate 19(2) 38-40 |
|
Pharmaceutical Benefits Advisory Committee
|
| secrecy of drug regulatory information (editorial) 25(4) 78-9 |
| comments 25(6) 130-1; 25(5) 103-4 |
|
Pharmaceutical Benefits Advisory Committee: answers to questions
|
| brand price premiums 23(2) 32 |
| terbinafine and fungal toenails (letter) 23(4) 72 |
| ATC classification of drugs in Schedule of Pharmaceutical Benefits 19(4) 101-3 |
|
Pharmaceutical Benefits Scheme
|
| ATC classification of drugs in schedule (PBAC question) 19(4) 101-3 |
| Australian and Ontario policies 25(6) 128-30 |
| brand price premiums (PBAC question) 23(2) 32 |
| cost effectiveness of drugs (editorial) 20(2) 26-7; 19(3) 58-9 |
| drug price reforms (editorial) 30(6) 138-40 |
| dyslipidaemia guidelines 21(4) 98-9 |
| economic analysis and the drug industry (editorial) 25(6) 126-7 |
| economic analysis and the drug industry (editorials) 22(3) 50-1 |
| emergency drugs - doctor's bag supplies 19(4) 89-92 |
| adenosine, activated charcoal and verapamil (PBAC question) 20(4) 86-7 |
| expensive drugs (editorial) 29(6) 146-8 |
| letter 30(3) 59-63 |
| expensive new drugs (editorial) 27(6) 136-7 |
| letter 28(3) 55-8 |
| morphine preparations (PBAC question) 19(4) 101-3 |
| policies 18(2) 41 |
| prescribing and the law (editorial) 27(5) 108-9 |
| letters 28(2) 29-33; 28(2) 29-33 |
| product information 17(2) 39-41 |
| sumatriptan 50mg tablets (PBAC question) 20(4) 86-7 |
| letter 21(3) 60-3 |
| transparency of information about new drugs (editorial) 28(4) 83-4 |
| US Free Trade Agreement (editorial) 27(3) 54-5 |
| letter 27(5) 109-13 |
| withdrawal of drugs from the market 26(3) 50-1 |
| letters 27(2) 28-33; 26(5) 99-102 |
|
pharmaceutical industry - see drug industry
|
|
pharmaceutical promotion - see advertising
|
|
pharmaceutical representatives
|
| pharmaceutical company representatives 23(5) 97-9 |
|
pharmacokinetics
|
| bioequivalence and generic drugs 26(4) 85-7 |
| letters 26(6) 124-5 |
| bisphosphonates 23(6) 130-2 |
| chiral drugs 27(2) 47-9 |
| correction 28(3) 55-8 |
| letter 27(5) 109-13 |
| Clinical pharmacology essentials - book review 24(4) 97 |
| cytochrome P450 system 24(1) 10-2 |
| letters 24(4) 80-2 |
| extended-release products 22(4) 88-90 |
| generic drugs 30(2) 41-3 |
| letters 30(4) 88-90 |
| hypoglycaemic drugs 24(4) 83-5 |
|
Pharmacokinetics made easy
|
| concentration-effect relationship 18(4) 102-4 |
| designing dose regimens 19(3) 76-8 |
| non-linear pharmacokinetics 17(2) 36-8 |
| phenacetin and analgesic nephropathy 23(1) 17-9 |
| publication of book 22(1) 19-20 |
| therapeutic drug monitoring 20(1) 9-11 |
| letters 20(3) 57-60 |
|
pharmacology - clinical and experimental pharmacology
|
| acid secretion inhibitors 23(3) 57-9 |
| angiogenesis inhibitors in cancer 29(1) 9-12; 29(1) 13-5 |
| antineoplastic antibodies 26(6) 141-3 |
| bisphosphonates 23(6) 130-2; 23(6) 133-6 |
| colorectal cancer drugs 25(5) 108-10; 25(5) 111-3 |
| COX inhibitors 23(2) 30-2 |
| Goodman & Gilman's 'The pharmacological basis of therapeutics' (book review) 29(1) 25 |
| immunosuppressants 29(4) 99-101; 29(4) 102-8 |
| thiazolidinediones 27(3) 67-70; 27(3) 70-4 |
| letter 27(6) 138-41 |
|
pharmacopoeias
|
| Paediatric pharmacopoeia - book review 26(2) 43 |
|
phenobarbitone
|
| clinical use of antiepileptics 17(1) 9-12 |
|
phenoxymethylpenicillin
|
| in Streptococcus pyogenes infection |
| letter 19(4) 92-3 |
| PBAC question 19(1) 6-7 |
|
phentermine
|
| in obesity 22(1) 12-6 |
|
phenytoin
|
| clinical use of antiepileptics 17(1) 9-12 |
| and gingival enlargement 26(1) 11-3 |
| hepatotoxicity (letter) 19(4) 92-3 |
| and thyroid dysfunction 17(3) 70-2 |
|
phosphate binders
|
| lanthanum carbonate hydrate - hyperphosphataemia in chronic renal failure - Fosrenol (New drug) 29(2) 53-5 |
|
photodynamic therapy
|
| in macular degeneration 25(5) 116-9 |
|
physical activity
|
| management of childhood obesity 26(2) 30-2 |
|
physical therapy
|
| back pain 17(2) 33-6 |
| letter - transcutaneous electrical nerve stimulation 18(1) 4-7 |
| osteoarthritis 18(1) 2-4 |
| letter 18(4) 84-6 |
|
Physiotens
|
| see moxonidine 29(1) 25-7 |
|
phytomenadione - haemorrhagic disease of the newborn
|
| Konakion (New formulation) 23(2) 45-6 |
|
pilocarpine
|
| management of xerostomia 29(4) 97-8 |
| letters 30(1) 3-4 |
|
pimecrolimus
|
| atopic dermatitis - Elidel (New drug) 26(6) 146-51 |
| letter 27(2) 28-33 |
|
pioglitazone
|
| pharmacology 27(3) 67-70; 27(3) 70-4 |
| letter 27(6) 138-41 |
| type 2 diabetes - Actos (New drug) 25(1) 20-3 |
|
piperacillin/tazobactam combination
|
| Tazocin (New drug) 17(3) 73 |
|
piroxicam
|
| new brand - Candyl 18(1) 7-9 |
| new brand - Candyl D 19(3) 81-3 |
|
pityriasis
|
| antifungal drugs 19(3) 72-5 |
|
placebo
|
| effects of injections 22(6) 145-7 |
|
plant extracts
|
| paclitaxel - ovarian cancer - Taxol (New drug) 17(4) 87-90 |
|
plasma volume expanders
|
| pentastarch - Voluven (New drug) 30(4) 107-11 |
|
plasma volume substitutes
|
| gelatin, succinylated - Geofusine (New drug) 22(1) 20-3 |
|
plasminogen activators
|
| reteplase - myocardial infarction - Rapilysin (New drug) 21(3) 80-3 |
| tenecteplase - myocardial infarction - Metalyse (New drug) 24(2) 43-7 |
|
platelet antagonists
|
| abciximab - coronary angioplasty - ReoPro (New drug) 19(3) 81-3 |
| aspirin dosages in thrombosis prevention 19(3) 79-81 |
| letter 20(1) 3-4 |
| aspirin vs warfarin in atrial fibrillation 18(3) 72-4 |
| clinical pharmacology 19(4) 98-101 |
| clopidogrel - Plavix (New drug) 22(2) 43-7 |
| coronary stents 30(4) 92-96 |
| eptifibatide - Integrilin (New drug) 26(6) 146-51 |
| in management of coronary disease 24(3) 56-8 |
| in management of stroke 22(4) 85-7 |
| tirofiban - Aggrastat (New drug) 22(4) 95-8 |
| warfarin interactions 25(4) 81-5 |
| aspirin and prosthetic heart valves (letter) 25(6) 131-2 |
|
Plavix
|
| see clopidogrel 22(2) 43-7 |
|
Plendil
|
| see felodipine 17(2) 30-2 |
|
plethysmography
|
| deep vein thrombosis 21(3) 76-9 |
|
pneumococcal conjugate vaccine
|
| Prevenar (New drug) 24(3) 71-5 |
|
pneumococcal vaccination
|
| recommendations 17(2) 41 |
| letter 18(1) 4-7 |
|
Pneumocystis carinii pneumonia
|
| atovaquone - Wellvone (New drug) 18(3) 58-9 |
|
pneumonia
|
| antibiotics 19(2) 48-51 |
| antibiotics and antibiotic resistance 22(2) 37-9 |
| influenza immunisation 25(1) 5-7 |
| management of aspiration pneumonia 26(1) 14-7 |
| moxifloxacin (Underneath the RADAR) 26(6) 131 |
|
Pocket guide to lung function tests
|
| book review 29(3) 70 |
|
poisoning
|
| activated charcoal 20(1) 14-6 |
| Amanita phalloides 23(2) 29 |
| drug screens 24(4) 90-1 |
| management of injuries by sea creatures 30(5) 117-21 |
| snake bites 29(5) 125-9 |
| spider bites 29(6) 156-8 |
|
poisons
|
| scheduling 20(1) 12-3 |
|
polidocanol
|
| laureth-9 - varicose veins - Aethoxysklerol (New drug) 25(1) 20-3 |
|
poliomyelitis
|
| childhood immunisations 17(4) 91-4 |
| post polio support groups - patient support organisations 17(4) 103 |
| vaccine - diphtheria, tetanus, pertussis, hepatitis B, polio and Haemophilus influenzae type b - Infanrix penta, Infanrix hexa and Infanrix IPV (New combinations) 27(6) 159-65 |
|
polycystic ovary syndrome
|
| drug treatment 27(5) 129-31 |
| letter 28(3) 55-8 |
|
polyethylene glycol
|
| in treatment of poisoning 20(1) 14-6 |
|
polymyalgia rheumatica
|
| corticosteroids 21(1) 11-4 |
|
polypharmacy
|
| editorial 31(1) 2-3 |
|
polypill
|
| prevention of cardiovascular disease (editorial) 28(4) 82-3 |
|
polysomnography
|
| diagnostic tests 21(2) 40-3 |
| letter 22(1) 3-5 |
|
population screening
|
| newborn hearing screening 26(4) 82-4 |
|
poractant alfa
|
| Curosurf - neonatal respiratory distress syndrome (New drug) 28(3) 75-9 |
|
posaconazole
|
| Noxafil - fungal infections (New drug) 29(3) 84-7 |
|
Posicor
|
| see mibefradil 21(2) 49-55 |
|
positron emission tomography
|
| in cardiology 18(1) 13-5 |
| expensive medical technology 17(3) 54-5 |
| letter 18(2) 27-9 |
| in neurology 18(1) 15-8 |
|
Postinor
|
| see levonorgestrel 25(4) 94-9 |
|
post-menopausal symptoms - see menopause
|
|
post-operative care
|
| dexmedetomidine - sedation - Precedex (New drug) 24(5) 129-31 |
| post-operative pain management 18(4) 88-91 |
|
potassium chloride, intravenous
|
| adverse effects 28(1) 14-6 |
| letter 28(4) 84-7 |
|
potassium clavulanate
|
| see clavulanic acid 17(3) 55-6 |
|
practice incentives
|
| Practice Incentives Program 23(3) 50-1; 23(3) 52-3 |
|
Pravachol
|
| see pravastatin 21(3) 80-3 |
|
pravastatin
|
| after myocardial infarction (editorial) 21(4) 86-7 |
| hypercholesterolaemia 22(5) 114-7 |
| letter 23(2) 27-8 |
| Pravachol (New strength) 21(3) 80-3 |
|
prazosin
|
| and postural hypotension 18(1) 21-2 |
|
prazosin hydrochloride
|
| DBL Prazosin (New brand) 23(2) 45-6 |
|
Precedex
|
| see dexmedetomidine 24(5) 129-31 |
|
prednisolone
|
| clinical pharmacology in asthma 19(2) 44-7 |
| clinical pharmacology in autoimmune diseases 22(1) 9-11 |
| in human milk (letter) 21(2) 31-4 |
| in rheumatology 21(1) 11-4 |
|
prednisone
|
| clinical pharmacology in asthma 19(2) 44-7 |
| in myasthenia gravis 30(6) 156-60 |
| in rheumatology 21(1) 11-4 |
|
pre-eclampsia
|
| biochemical tests for abnormalities in pregnancy (letter) 29(4) 91-3 |
|
pregabalin
|
| Lyrica - epilepsy, neuropathic pain (New drug) 28(3) 75-9 |
|
pregnancy - see also birth defects
|
| abnormal laboratory results - biochemical tests 28(4) 98-101 |
| letters 29(1) 3-5; 28(6) 136-9 |
| antidepressants 30(5) 125-7 |
| antipsychotics 30(6) 162-3 |
| biochemical tests for abnormalities 29(2) 48-52 |
| letter 29(4) 91-3 |
| 'Drugs and pregnancy' (book review) 25(1) 11 |
| influenza vaccination 24(5) 116-9 |
| letter 25(1) 4 |
| metformin and diabetes 30(3) 68-9 |
| new antidepressants 18(4) 92-6 |
| register of anticonvulsant users 23(2) 43 |
| Rhesus D immunoglobulin 23(2) 36-8 |
| letter 24(4) 80-2 |
|
premenstrual dysphoric disorder
|
| treatment with antidepressants 28(4) 91-3 |
|
premenstrual syndrome
|
| agnus castus fruit 24(5) 123 |
|
Premia
|
| see oestrogen medroxyprogesterone combination 24(6) 155-8 |
|
Premia Low
|
| see oestrogens, conjugated and medroxyprogesterone 27(1) 21-3 |
|
prenatal diagnosis
|
| DNA tests - approach and techniques 18(2) 45-8 |
| DNA tests - clinical applications 18(3) 76-9 |
| test for von Hippel Lindau syndrome - letter 19(1) 3-6 |
|
prescribing patterns, costs, etc. - see drug utilisation; cost of drugs
|
|
Prevenar
|
| see pneumococcal conjugate vaccine 24(3) 71-5 |
|
preventative medicine
|
| the polypill and cardiovascular disease (editorial) 28(4) 82-3 |
|
Prexige
|
| see lumiracoxib 29(1) 25-7 |
|
Prezista
|
| see darunavir 30(3) 79-82 |
|
price of drugs - see cost of drugs
|
|
prilocaine
|
| lignocaine patch - new formulation - EMLA Patch 17(4) 87-90 |
|
Primacin
|
| see primaquine 22(5) 103-5; 22(3) 70-1 |
|
primaquine
|
| malaria - Primacin (New drug) 22(3) 70-1 |
| letter 22(5) 103-5 |
|
primary health care
|
| 'Aboriginal primary health care' (book review) 27(1) 9 |
| 'CARPA Standard Treatment Manual' (book review) 27(1) 8 |
|
primidone
|
| clinical use of antiepileptics 17(1) 9-12 |
|
Primovist
|
| see disodium gadoxetate 29(3) 84-7 |
|
Priorix
|
| see measles, mumps, rubella vaccine 22(4) 95-8 |
|
Pro-Epanutin
|
| see fosphenytoin 23(5) 110-1 |
|
progesterone
|
| Crinone 8% (New formulation) 26(5) 118-9 |
| fertility testing - abnormal laboratory results 25(2) 38-40 |
|
progestogens
|
| contraceptive doses missed by users 25(1) 16-8 |
| letter 25(3) 51-3 |
| drospirenone/ethinylestradiol - contraceptive - Yasmin (New drug) 25(6) 147-51 |
| progestogen-only contraceptives 22(1) 6-8 |
| risk of thromboembolism 25(3) 57-9 |
|
progestogens - menopause - hormone replacement
|
| regimens 17(1) 13-6 |
| oestrogens and progestogens after hysterectomy (letter) 17(4) 79-81 |
|
Prograf
|
| see tacrolimus 22(2) 28-31; 21(3) 80-3 |
|
Prohance
|
| see gadoteridol 25(2) 44-7 |
|
Proleukin
|
| see aldesleukin 23(4) 84-7 |
|
propofol
|
| Propofol injection (New brand) 24(4) 100-2 |
| Propofol-BC (New brand) 25(4) 94-9 |
|
Proscar
|
| see finasteride 17(1) 6-8 |
|
prostacyclin
|
| epoprostenol - primary pulmonary hypertension - Flolan (New drug) 25(6) 147-51 |
| iloprost - Ventavis - pulmonary hypertension (New drug) 27(3) 76-9 |
|
prostacyclin analogues
|
| treprostinil - pulmonary arterial hypertension - Remodulin (New drug) 27(6) 159-65 |
|
prostaglandin E1
|
| alprostadil - erectile dysfunction - Caverject (New strength) 22(2) 43-7; 18(3) 58-9 |
| erectile dysfunction 21(2) 46-8 |
|
prostaglandin F2 alpha
|
| bimatoprost - glaucoma - Lumigan (New drug) 26(1) 22-3 |
| latanoprost - glaucoma - Xalatan (New drug) 21(2) 49-55 |
| travoprost - raised intraocular pressure - Travatan (New drug) 25(3) 74-5 |
|
prostate specific antigen
|
| costs of tests (letter) 17(1) 4-5 |
|
prostatic cancer
|
| bicalutamide - anti androgen - Cosudex (New drug) 19(4) 108-11 |
| diagnosis in patients taking dihydropyridines 20(1) 3-4 |
| flutamide and bicalutamide (PBAC question) 22(4) 99 |
| management 19(1) 22-4 |
| nilutamide - anti androgen - Anandron (New drug) 20(2) 45-51 |
| prostate specific antigen - costs of tests (letter) 17(1) 4-5 |
|
prostatic hypertrophy, benign
|
| complementary medicine - saw palmetto 23(4) 79 |
| drug treatment 18(2) 30-2 |
| finasteride - Proscar (New drug) 17(1) 6-8 |
| in pharmacokinetics 18(4) 102-4 |
| prothrombin gene 22(3) 63-6 |
| tamsulosin hydrochloride - Flomax (New drug) 23(3) 64-7 |
| terazosin hydrochloride - Hytrin (New drug) 18(1) 7-9 |
| urinary obstruction and drug costs and benefits (editorial) 18(2) 26-7 |
| letter 19(1) 3-6 |
|
protein C
|
| Ceprotin - congenital protein C deficiency (New drug) 30(2) 50-55 |
| recombinant protein C - drotrecogin alfa - sepsis - Xigris (New drug) |
Home